Is PLRZ or PMVP more undervalued in 2026?

CirclFi compares Polyrizon Ltd. (PLRZ) and PMV Pharmaceuticals, Inc. (PMVP) using 13 institutional-grade valuation models. PLRZ has a Quality of Company score of 2.3/10 while PMVP scores 4.5/10.

Which is a better buy — PLRZ or PMVP?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PLRZ and PMVP valuations compare?

PLRZ at $16.50 and PMVP at $1.19 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PLRZ vs PMVP Valuation Comparison 2026 — Intrinsic Value Analysis

PLRZ

Biotechnology

Polyrizon Ltd.

Quality

2.3

out of 10

Value Trap

—

Price

$16.50

Last close

Models

9/13

Active

PMVP

Biotechnology

PMV Pharmaceuticals, Inc.

Quality

4.5

out of 10

Value Trap

SAFE

Price

$1.19

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	PLRZ Fair Value	PLRZ Upside	PMVP Fair Value	PMVP Upside
Bayesian DCF	Intrinsic	$4.37	-73.5%	$0.52	-56.2%
Earnings Power Value	Intrinsic	—	—	$0.94	-32.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$18.67	+13.1%	—	—
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PLRZ vs PMVP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PLRZ vs PMVP — Which Stock Is More Undervalued?

PMVP scores higher with a 4.5/10 quality rating vs PLRZ's 2.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Polyrizon Ltd. (PLRZ) and PMV Pharmaceuticals, Inc. (PMVP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PLRZ currently trades at $16.50 with a QOC of 2.3/10, while PMVP trades at $1.19 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).